Lewis retired from Mintz in 2025. He was previously a Member in the firm's Corporate Practice.
viewpoints
Mintz Venture Watch — Volume 5: A Report on Deal Trends from Q1 and Q2 2023
August 21, 2023 | Article | By Daniel DeWolf, Lewis Geffen, Jeremy Glaser
Despite choppy market conditions for private companies, the Mintz Venture Capital & Emerging Companies team remained busy advising emerging companies of all sizes and at all stages of growth across a wide range of industries. For the first half of 2023 we completed 72 transactions, with an aggregate deal value in excess of $1.6 billion. Below are a few highlighted transactions:
Mintz Venture Watch — Volume 4: A Report on Deal Trends from 2022
February 9, 2023 | Article | By Daniel DeWolf, Lewis Geffen, Jeremy Glaser
This edition of Mintz Venture Watch reports on the firm’s VC transaction activity in 2022, including data for Q3 and Q4. Mintz represented issuers and investors in the life sciences, cybersecurity, energy, and other sectors in more than 128 transactions valued at more than $3 billion in 2022.
Mintz Venture Watch — Volume 3: A Report on Deal Trends from Q1 and Q2 2022
August 17, 2022 | Article | By Daniel DeWolf, Lewis Geffen, Jeremy Glaser
Mintz Venture Watch — Volume 2: A Report on Deal Trends from Q3 and Q4 2021
February 9, 2022 | Article | By Daniel DeWolf, Lewis Geffen, Jeremy Glaser
Mintz Venture Watch — Volume 1: A Report on Deal Trends from Q1 and Q2 2021
August 10, 2021 | Article | By Daniel DeWolf, Lewis Geffen, Jeremy Glaser
Webinar Recording: Incubating and Launching New Life Science Companies
March 9, 2021 | Webinar | By Lewis Geffen
CAUTION: Director Veto Rights in Financing Documents May Constitute “Disproportionate Voting”
January 2, 2019 | Article | By Lewis Geffen
News & Press
Events & Speaking
Recognition & Awards
Best Lawyers in America: Biotechnology and Life Sciences Practice (2021 - 2023, 2026); Corporate Law (2021 – 2026)
Recognized by The Legal 500 United States as “a well-known life sciences expert” for Venture Capital and Emerging Companies (2014)
Recommended by The Legal 500 United States for Venture Capital and Emerging Companies (2013 – 2018; 2021 – 2022, 2024); Healthcare: Life Sciences (2020 – 2022, 2024)
Martindale-Hubbell AV Preeminent

